Finally, NaB improves the intestinal microenvironment by increasing the relative abundance of beneficial gut bacteria, reducing CRC progression (20), and enhancing the effects of anti-PD-1 and anti-PD-L1 therapies against CRC (21). The gene discussed is CD274; the disease is colorectal carcinoma.